Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrique Crisman

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Antioxidants (Basel, Switzerland)|February 25, 2022
Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's DiseasePablo Duarte, Patrycja Michalska, Enrique Crisman, et al.
Medicinal Research Reviews|April 28, 2024
Innovative pathological network-based multitarget approaches for Alzheimer's disease treatmentPaloma Mayo, Jorge Pascual, Enrique Crisman, et al.
Medicinal Research Reviews|September 10, 2022
KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potentialEnrique Crisman, Pablo Duarte, Esteban Dauden, et al.
Antioxidants (Basel, Switzerland)|January 21, 2022
Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157-Lipoic Acid Hybrids for the Treatment of Alzheimer's DiseaseÁngel Cores, Patrycja Michalska, José Miguel Pérez, et al.
Journal of Medicinal Chemistry|January 17, 2025
Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic NeuroinflammationPablo Duarte, Francisco J Sanchez-Porro, Enrique Crisman, et al.
Chembiochem : a European Journal of Chemical Biology|May 17, 2019
Characterisation of the Dynamic Interactions between Complex N-Glycans and Human CD22Cristina Di Carluccio, Enrique Crisman, Yoshiyuki Manabe, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Antioxidants (Basel, Switzerland)|February 25, 2022
Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's DiseasePablo Duarte, Patrycja Michalska, Enrique Crisman, et al.
Medicinal Research Reviews|April 28, 2024
Innovative pathological network-based multitarget approaches for Alzheimer's disease treatmentPaloma Mayo, Jorge Pascual, Enrique Crisman, et al.
Medicinal Research Reviews|September 10, 2022
KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potentialEnrique Crisman, Pablo Duarte, Esteban Dauden, et al.
Antioxidants (Basel, Switzerland)|January 21, 2022
Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157-Lipoic Acid Hybrids for the Treatment of Alzheimer's DiseaseÁngel Cores, Patrycja Michalska, José Miguel Pérez, et al.
Journal of Medicinal Chemistry|January 17, 2025
Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic NeuroinflammationPablo Duarte, Francisco J Sanchez-Porro, Enrique Crisman, et al.
Chembiochem : a European Journal of Chemical Biology|May 17, 2019
Characterisation of the Dynamic Interactions between Complex N-Glycans and Human CD22Cristina Di Carluccio, Enrique Crisman, Yoshiyuki Manabe, et al.
Pageof 1